Healthcare: Is It (Finally) OK To Buy Valeant and Gilead Sciences Again?
Industry Focus
The Motley Fool
4.6 • 854 Ratings
🗓️ 17 May 2017
⏱️ 24 minutes
🧾️ Download transcript
Summary
We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust.
Thanks to Slack for supporting The Motley Fool. Learn more at slack.com.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Thanks to Slack for supporting the Motley Fool. |
| 0:02.0 | Slack is a messaging app which brings together all of your team's communications in one place, |
| 0:07.0 | making work simpler and more productive. |
| 0:09.0 | Go to Slack.com to learn more. |
| 0:11.0 | Welcome to Industry Focus, the podcast that... to learn more. |
| 0:13.0 | Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day. |
| 0:18.0 | It is May 17th, and I'm your health care show host Christine Hargis. |
| 0:22.0 | I'm on the phone with Todd Campbell a |
| 0:24.1 | fool.com health care writer Todd welcome to the show as usual. |
| 0:27.6 | Hi Christine how are you today? I'm doing all right I'm getting ready for a trip to Toronto tomorrow so pretty wired that it's basically my Friday. |
| 0:36.0 | Oh excellent I hope you have a great time I've always wanted to be up there. I have yet to travel up there yet. |
| 0:42.0 | Yeah, I haven't been either. |
| 0:43.0 | So listeners, if you listen to this before I actually go, which is tomorrow the 18th, |
| 0:48.0 | please shoot me a note at industry focus at fool.com. |
| 0:50.0 | I will take all the recommendations that you guys have for restaurants |
| 0:54.0 | and I hear there's a good music scene and anything else that comes to mind. I'll be in Toronto and also Niagara Falls. |
| 0:59.4 | So that should be fun. So before I go, we are talking on the show today about two companies that have been incredibly |
| 1:07.8 | beaten up by traders over the past couple of years and are both arguably value stocks right now. |
| 1:14.0 | So we're going to be talking about both Valiant Pharmaceuticals and Gilead Sciences. |
| 1:18.0 | Todd, which one do you want to start with? |
| 1:20.0 | Well, let's start up with Valiant, because of the two that's the one that's probably been been beaten up most. |
| 1:27.0 | And I know that if you've been an investor in Valiant, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.